{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:30:55Z","timestamp":1759537855483,"version":"build-2065373602"},"reference-count":82,"publisher":"Informa UK Limited","issue":"13","funder":[{"name":"Blood Cancer Research"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2025,9,2]]},"DOI":"10.1080\/14656566.2025.2556138","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T05:11:36Z","timestamp":1756962696000},"page":"1415-1432","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Recent advances and future directions in newly diagnosed mantle cell lymphoma"],"prefix":"10.1080","volume":"26","author":[{"given":"Wan Danial","family":"Noor","sequence":"first","affiliation":[{"name":"Sir Charles Gairdner Hospital","place":["Nedlands, Australia"]},{"name":"Linear Clinical Research","place":["Nedlands, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan Yoon","family":"Cheah","sequence":"additional","affiliation":[{"name":"Sir Charles Gairdner Hospital","place":["Nedlands, Australia"]},{"name":"Linear Clinical Research","place":["Nedlands, Australia"]},{"name":"University of Western Australia","place":["Nedlands, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"e_1_3_5_3_1","first-page":"446","volume-title":"WHO Classification of Tumours: Haematolymphoid Tumours","author":"Klapper W","year":"2024","unstructured":"Klapper W, Ferry JA, Medeiros LJ, et al. Mantle cell lymphoma [internet]. In: Coupland SE, Ott G, Sewell WA, editors. WHO Classification of Tumours: Haematolymphoid Tumours [Internet]. 5th ed. Vol. 11. Lyon (France): International Agency for Research on Cancer; 2024 [cited 2025 Mar 1]. p. 446\u2013452. Available from: https:\/\/tumourclassification.iarc.who.int\/chaptercontent\/63\/138","edition":"5"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.201350"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx333"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-189505"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01977-y"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-369629"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00195-2"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01520-7"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2202672"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09174.x"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14241"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01780"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00739-X"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01198-2"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00184-3"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-212973"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194641"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3163_101"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70115"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201817"},{"issue":"1","key":"e_1_3_5_27_1","first-page":"309","article-title":"Acalabrutinib plus bendamustine rituximab untreated mantle cell lymphoma: results from phase 3, double-blind, placebo-controlled ECHO trial","volume":"9","author":"Wang M","year":"2024","unstructured":"Wang M, Mayer J, Belada D. Acalabrutinib plus bendamustine rituximab untreated mantle cell lymphoma: results from phase 3, double-blind, placebo-controlled ECHO trial. EHA 2024 Congr Abstract LB3439 Presented. 2024;9(S1):309\u2013310.","journal-title":"EHA 2024 Congr Abstract LB3439 Presented"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00690"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182942"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70096_614"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13429"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001355"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13929"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-201441"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200735"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01586"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70096_603"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02698"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.12.634"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13796"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-523845"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70096_619"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00605"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00899"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7503"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009744"},{"issue":"1","key":"e_1_3_5_50_1","first-page":"1173","article-title":"Minimal residual disease with bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: results from the phase 3 ECHO trial","volume":"9","author":"Wang ML","year":"2025","unstructured":"Wang ML, Spurgeon S, Pavlovsky M, et al. Minimal residual disease with bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: results from the phase 3 ECHO trial. HemaSphere. 2025;9(S1):1173\u20131174.","journal-title":"HemaSphere"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70096_607"},{"key":"e_1_3_5_52_1","unstructured":"Food and Drug Administration. Pharmacyclics LLC.; withdrawal of approval of indications for mantle cell lymphoma and marginal zone lymphoma for IMBRUVICA (ibrutinib) capsules and tablets [internet]. Federal Register. 2023 [cited 2025 Aug 7]. Available from: https:\/\/www.federalregister.gov\/documents\/2023\/12\/18\/2023-27662\/pharmacyclics-llc-withdrawal-of-approval-of-indications-for-mantle-cell-lymphoma-and-marginal-zone"},{"key":"e_1_3_5_53_1","unstructured":"Center for Drug Evaluation Research. Fda approves acalabrutinib with bendamustine and rituximab for previously untreated mantle cell lymphoma [Internet]. U.S. Food and Drug Administration. FDA; 2025 [cited 2025 Aug 7]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-acalabrutinib-bendamustine-and-rituximab-previously-untreated-mantle-cell-lymphoma"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412096"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.191429"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024023962"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010606"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3163_98"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199710"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-192939"},{"issue":"1","key":"e_1_3_5_61_1","first-page":"3280","article-title":"Zr study: a prospective phase II study of zanubrutinib-rituximab chemo-free therapy with or without autologous stem cell transplantation in newly diagnosed mantle cell lymphoma","volume":"9","author":"Qu C","year":"2025","unstructured":"Qu C, Ping N, Zou R, et al. Zr study: a prospective phase II study of zanubrutinib-rituximab chemo-free therapy with or without autologous stem cell transplantation in newly diagnosed mantle cell lymphoma. HemaSphere. 2025;9(S1):3280\u20133282.","journal-title":"HemaSphere"},{"issue":"1","key":"e_1_3_5_62_1","first-page":"1163","article-title":"Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study","volume":"9","author":"von Keudell G","year":"2025","unstructured":"von Keudell G, Hoffmann M, Wr\u00f3bel T, et al. Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study. HemaSphere. 2025;9(S1):1163\u20131164.","journal-title":"HemaSphere"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194357"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012424"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025563"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204495"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009992"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02272-0"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0794"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207372"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008727"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204691"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174718"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70093_135"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70093_48"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022354"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-209480"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779736"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27044"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02287"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70093_46"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00638-0"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285845"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70096_846"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2025.2556138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:34:20Z","timestamp":1759480460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2025.2556138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":82,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,9,2]]}},"alternative-id":["10.1080\/14656566.2025.2556138"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2025.2556138","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"type":"print","value":"1465-6566"},{"type":"electronic","value":"1744-7666"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-06-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}